Epithelial ovarian cancer: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[File:Downstream effect of p53 mutation..jpg|alt=Downstream effect of p53 mutation|center|frame|Downstream effect of p53 mutation.]] | [[File:Downstream effect of p53 mutation..jpg|alt=Downstream effect of p53 mutation|center|frame|Downstream effect of p53 mutation.<ref name="pmid26082798">{{cite journal |vauthors=Pantziarka P |title=Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche |journal=Ecancermedicalscience |volume=9 |issue= |pages=541 |date=2015 |pmid=26082798 |pmc=4462886 |doi=10.3332/ecancer.2015.541 |url=}}</ref>]] | ||
{{Epithelial ovarian cancer}} | {{Epithelial ovarian cancer}} | ||
{{CMG}}{{AE}}{{HMHJ}} | {{CMG}}{{AE}}{{HMHJ}} | ||
Revision as of 18:44, 25 February 2019
Template:Epithelial ovarian cancer Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]
- ↑ Pantziarka P (2015). "Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche". Ecancermedicalscience. 9: 541. doi:10.3332/ecancer.2015.541. PMC 4462886. PMID 26082798.